Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Bristol Myers Squibb International Corporation
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Phase 1/2 Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-863233 in Subjects with Advanced and/or Metastatic Solid Tumors
- Phase 1 (Dose Escalation): to define the safety, tolerability, dose-limiting toxicities (DLTs) and Maximum Tolerated Dose (MTD) of BMS-863233 administered orally to subjects with advanced and/or met...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
Effect of a High-Fat or a Light Meal Relative to Fasting Conditions on the Pharmacokinetics of Atazanavir when Administered with Ritonavir in Healthy Subjects
To assess, in healthy subjects, the effect of a light or high-fat meal on the single dose pharmacokinetics of ATV 300 mg, when administered in combination with RTV 100 mg.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Phase 2, Placebo-Controlled, Randomized, Double-Blind, Parallel Arm, Dose Ranging Study to Evaluate Safety and Efficacy of Apixaban In Patients with a Recent Acute Coronary Syndrome. Revised Protocol 01 incorporating Amendment 03 And Parmacogenetics Blood Sample Amendment 01 dated 17-Feb-2006 Revised Protocol 02 incorporating Amendment 04 and Admin Letter 01
The primary objective of this study is to evaluate 4 doses of apixaban as compared to placebo over a 26 week treatment period in selected subjects with recent (≤7 days) Acute Coronary Syndrome (ACS) f...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Phase 3, Randomized, Double-blind, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Apixaban in Subjects Undergoing Elective Total Hip Replacement Surgery (The ADVANCE-3 study Apixaban Dosed Orally Versus Anti-Coagulation with Injectable Enoxaparin to Prevent Venous Thromboembolism) +Pharmacogenetics Blood Sample Amendment 01 (Version 1.0 - dated 27-Nov-2006) Revised Protocol 02, incorporating Protocol Amedment 02 & 04 and Admin Letter 01 (Version 3.0, Dated 21-Jun-2007)
To compare the effect of oral (PO) apixaban 2.5 mg BID versus subcutaneous (SC) enoxaparin 40 mg QD on the composite endpoint of adjudicated asymptomatic and symptomatic deep-vein thrombosis (DVT), no...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
Evaluation of Belatacept as First-line Immunosuppression in De Novo Liver Transplant Recipients Revised Protocol 01, incorporating protocol amendment 02 (Version 1.0, dated 22-Oct-2007). And Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 2.0, dated 20-Jul-2007). Evaluación de belatacept como inmunosupresión de primera línea en receptores de novo de un trasplante de hígado. Protocolo Revisado 1, que incorpora la Enmienda 2 al protocolo (Versión 1.0, de fecha 22-Oct-2007). Y Enmienda 1 al protocolo para la obtención de muestras de sangre para farmacogenética - Específica de centro (versión 2.0, de fecha 20-Jul-2007)
To evaluate the effects of belatacept-based immunosuppression, relative to tacrolimus, on the incidence of AR (clinically suspected and biopsy-proven), graft loss and death by 6 months
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Multi-Center Single Arm Phase II Study of MDX-010 (BMS-734016) Monotherapy in Patients with Previously Treated Unresectable Stage III or IV Melanoma. Revised Protocol 01, incorporating Amendment 02; and Pharmacogenetics Blood Sample Amendment #01, version 1.0 dated 01-Jul-05, Pharmacogenomics Archived Tissue Sample Amendment #03, version 1 dated 29-Mar-06 and Pharmacogenomic Biomarker Sample Amendment #04, version 1 dated 03-Apr-06
To evaluate the Best Overall Response Rate (BORR), (as per modified WHO criteria) in patients with previously treated Stage III (unresectable) or Stage IV melanoma receiving ipilimumab.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
Study of the Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection. Estudio de la actividad antiviral de entecavir en pacientes que reciben trasplante hepático por infección crónica con el virus de la hepatitis B Revised Protocol 01, incorporating Amendment 02 (Version 1.0 Date 20-Nov-2006). And Pharmacogenetics Blood Sample Amendment 01 - Site Specific (Version 1.0 Date 20-Nov-2006)
Efficacy: To determine the proportion of patients who experience virological recurrence of HBV at 72 weeks post-OLT as measured by HBV DNA by PCR >= 50 IU/mL (approximately >= 300 copies/mL).
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
Pomalidomide/Dexamethasone With or Without Elotuzumab in Multiple Myeloma that is resistant to treatment
To compare progression free survival (PFS) between treatment arms
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
Efficay and safety study of Nivolumab in subjects with Primary Central Nervous System Lymphoma (PCNSL) and Primary Testicular Lymphoma (PTL)
To assess the clinical benefit of nivolumab in subjects with relapsed/refractory PCNSL or relapsed/refractory PTL as measured by ORR by blinded Independent Central Review (BICR).
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
Multicenter, Open-Label Study to Assess Early Response to Abatacept with Background Methotrexate Using Power Doppler Ultrasonography in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
To assess the occurrence of early signs of response to abatacept with background methotrexate, as defined by improvement of synovitis measured by Power Doppler Ultrasonography of the affected metacarp...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
9
10
Suivant